NO793474L - Antikoaguleringsmiddel og fremgangsmaate for fremstilling derav - Google Patents

Antikoaguleringsmiddel og fremgangsmaate for fremstilling derav

Info

Publication number: NO793474L
Authority: NO; Norway
Prior art keywords: anticoagulant; polysaccharide; heparin; range; cofactor
Prior art date: 1978-11-01

Application number

NO793474A

Other languages

English (en)

Norwegian (no)

Inventor

Gunnvoer Rothman

Ulf Sven Erik Rothman

Original Assignee

Akzo Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-11-01

Filing date

1979-10-29

Publication date

1980-05-05

1979-10-29 Application filed by Akzo Nv filed Critical Akzo Nv

1980-05-05 Publication of NO793474L publication Critical patent/NO793474L/no

Links

238000000034 method Methods 0.000 title claims description 22
239000003146 anticoagulant agent Substances 0.000 claims abstract description 48
150000004676 glycans Chemical class 0.000 claims abstract description 31
229920001282 polysaccharide Polymers 0.000 claims abstract description 31
239000005017 polysaccharide Substances 0.000 claims abstract description 31
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 26
241000237536 Mytilus edulis Species 0.000 claims abstract description 24
108090000190 Thrombin Proteins 0.000 claims abstract description 23
229960004072 thrombin Drugs 0.000 claims abstract description 21
235000020638 mussel Nutrition 0.000 claims abstract description 18
241000237852 Mollusca Species 0.000 claims abstract description 13
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 13
XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims abstract description 12
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 4
229940127219 anticoagulant drug Drugs 0.000 claims description 40
238000006243 chemical reaction Methods 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 12
230000008569 process Effects 0.000 claims description 9
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims description 8
239000000463 material Substances 0.000 claims description 8
230000019635 sulfation Effects 0.000 claims description 8
238000005670 sulfation reaction Methods 0.000 claims description 8
238000000605 extraction Methods 0.000 claims description 7
230000007062 hydrolysis Effects 0.000 claims description 7
238000006460 hydrolysis reaction Methods 0.000 claims description 7
230000002401 inhibitory effect Effects 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 5
159000000000 sodium salts Chemical class 0.000 claims description 5
235000013372 meat Nutrition 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
239000003929 acidic solution Substances 0.000 claims description 2
239000013543 active substance Substances 0.000 claims description 2
238000005903 acid hydrolysis reaction Methods 0.000 claims 1
239000004615 ingredient Substances 0.000 claims 1
229920006395 saturated elastomer Polymers 0.000 claims 1
229940127090 anticoagulant agent Drugs 0.000 abstract description 8
239000003795 chemical substances by application Substances 0.000 abstract description 6
238000001556 precipitation Methods 0.000 abstract description 4
229920000669 heparin Polymers 0.000 description 42
229960002897 heparin Drugs 0.000 description 41
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 40
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
239000000243 solution Substances 0.000 description 33
239000002244 precipitate Substances 0.000 description 31
239000000047 product Substances 0.000 description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
230000015271 coagulation Effects 0.000 description 16
238000005345 coagulation Methods 0.000 description 16
239000000126 substance Substances 0.000 description 16
238000011282 treatment Methods 0.000 description 15
230000002429 anti-coagulating effect Effects 0.000 description 13
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 11
229940122388 Thrombin inhibitor Drugs 0.000 description 11
230000000694 effects Effects 0.000 description 11
239000003868 thrombin inhibitor Substances 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
239000008280 blood Substances 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
208000007536 Thrombosis Diseases 0.000 description 9
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
238000009835 boiling Methods 0.000 description 8
239000000843 powder Substances 0.000 description 8
239000007858 starting material Substances 0.000 description 8
108010074860 Factor Xa Proteins 0.000 description 7
108010049003 Fibrinogen Proteins 0.000 description 7
102000008946 Fibrinogen Human genes 0.000 description 7
229940012952 fibrinogen Drugs 0.000 description 7
238000004108 freeze drying Methods 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
108010014173 Factor X Proteins 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
238000001914 filtration Methods 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
241000237519 Bivalvia Species 0.000 description 5
241000700159 Rattus Species 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
235000020639 clam Nutrition 0.000 description 5
239000012153 distilled water Substances 0.000 description 5
239000002994 raw material Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
102000009123 Fibrin Human genes 0.000 description 4
108010073385 Fibrin Proteins 0.000 description 4
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
229920002683 Glycosaminoglycan Polymers 0.000 description 4
102000007625 Hirudins Human genes 0.000 description 4
108010007267 Hirudins Proteins 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
229950003499 fibrin Drugs 0.000 description 4
229940006607 hirudin Drugs 0.000 description 4
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
241000237502 Ostreidae Species 0.000 description 3
108010094028 Prothrombin Proteins 0.000 description 3
102100027378 Prothrombin Human genes 0.000 description 3
230000023555 blood coagulation Effects 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
235000020636 oyster Nutrition 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
229940039716 prothrombin Drugs 0.000 description 3
229950003937 tolonium Drugs 0.000 description 3
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
AAQFSZFQCXLMNT-ACMTZBLWSA-N (3s)-3-amino-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid;hydrochloride Chemical compound Cl.OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 AAQFSZFQCXLMNT-ACMTZBLWSA-N 0.000 description 2
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
102000004411 Antithrombin III Human genes 0.000 description 2
108090000935 Antithrombin III Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000238366 Cephalopoda Species 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
229960005348 antithrombin iii Drugs 0.000 description 2
WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
229910001626 barium chloride Inorganic materials 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000004159 blood analysis Methods 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000012467 final product Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940046892 lead acetate Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
230000001376 precipitating effect Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
238000004448 titration Methods 0.000 description 2
239000002699 waste material Substances 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
241000237858 Gastropoda Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010073069 Hepatic cancer Diseases 0.000 description 1
241000545744 Hirudinea Species 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000237524 Mytilus Species 0.000 description 1
206010050902 Postoperative thrombosis Diseases 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
235000005811 Viola adunca Nutrition 0.000 description 1
240000009038 Viola odorata Species 0.000 description 1
235000013487 Viola odorata Nutrition 0.000 description 1
235000002254 Viola papilionacea Nutrition 0.000 description 1
244000172533 Viola sororia Species 0.000 description 1
XLDIAUNLPWGNHO-NUPNHORYSA-N [1-amino-3-[(3s,6s)-6,13-dimethyl-10-methylidene-2,5,9,12-tetraoxo-14-[(5e,7e)-3,7,10-trimethyl-4-oxoheptadeca-5,7-dienyl]-1-oxa-4,8,11-triazacyclotetradec-3-yl]-1-oxopropan-2-yl] hydrogen sulfate Chemical compound CCCCCCCC(C)C\C=C(/C)\C=C\C(=O)C(C)CCC1OC(=O)[C@H](CC(OS(O)(=O)=O)C(N)=O)NC(=O)[C@@H](C)CNC(=O)C(=C)NC(=O)C1C XLDIAUNLPWGNHO-NUPNHORYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
PGWTYMLATMNCCZ-UHFFFAOYSA-M azure A Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 PGWTYMLATMNCCZ-UHFFFAOYSA-M 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
229940045511 barium chloride Drugs 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
238000011033 desalting Methods 0.000 description 1
ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
229960000907 methylthioninium chloride Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
KKNIUBFRGPFELP-UHFFFAOYSA-N secretolin Chemical compound N=1C=CNC=1CC(N)C(=O)NC(CO)C(=O)NC(CC(O)=O)C(=O)NCC(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(=O)NC(CO)C(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(O)=O)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(O)=O)C(C)O)CC1=CC=CC=C1 KKNIUBFRGPFELP-UHFFFAOYSA-N 0.000 description 1
206010040560 shock Diseases 0.000 description 1
230000035939 shock Effects 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000002885 thrombogenetic effect Effects 0.000 description 1
150000004992 toluidines Chemical class 0.000 description 1
XLDIAUNLPWGNHO-UHFFFAOYSA-N topostatin Natural products CCCCCCCC(C)CC=C(C)C=CC(=O)C(C)CCC1OC(=O)C(CC(OS(O)(=O)=O)C(N)=O)NC(=O)C(C)CNC(=O)C(=C)NC(=O)C1C XLDIAUNLPWGNHO-UHFFFAOYSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Materials Engineering (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Polymers & Plastics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Seal Device For Vehicle (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

NO793474A 1978-11-01 1979-10-29 Antikoaguleringsmiddel og fremgangsmaate for fremstilling derav NO793474L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE7811306A SE7811306L (sv)	1978-11-01	1978-11-01	Antikoagulationsmedel samt sett for dess framstellning

Publications (1)

Publication Number	Publication Date
NO793474L true NO793474L (no)	1980-05-05

Family

ID=20336233

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO793474A NO793474L (no)	1978-11-01	1979-10-29	Antikoaguleringsmiddel og fremgangsmaate for fremstilling derav

Country Status (13)

Country	Link
EP (1)	EP0011322B1 (de)
JP (1)	JPS5564523A (de)
AT (1)	ATE945T1 (de)
AU (1)	AU5204579A (de)
DE (1)	DE2962725D1 (de)
DK (1)	DK459679A (de)
ES (1)	ES485623A1 (de)
FI (1)	FI793375A7 (de)
NO (1)	NO793474L (de)
NZ (1)	NZ191991A (de)
PT (1)	PT70352A (de)
SE (1)	SE7811306L (de)
ZA (1)	ZA795596B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57130918A (en) *	1981-02-09	1982-08-13	Cosmo Co Ltd	Preparation of antitumor agent
JPS5927831A (ja) *	1982-08-09	1984-02-14	Cosmo Co Ltd	抗腫瘍性物質
FR2538404B1 (de) *	1982-12-28	1985-08-23	Anic Spa
FR2584728B1 (fr) *	1985-07-12	1987-11-20	Choay Sa	Procede de sulfatation de glycosaminoglycanes et de leurs fragments
SE453394B (sv) *	1986-07-07	1988-02-01	Pharmacia Ab	Forfarande for framstellning av sulfaterade polysackarider genom anvendning av ett reducerande medel for sulfateringsreaktionen
EP0421508B1 (de) *	1989-10-04	1993-12-15	Akzo Nobel N.V.	Sulfatierte Glykosaminoglykuronane mit antithrombotischer Wirkung.
IT1237518B (it) *	1989-11-24	1993-06-08	Renato Conti	Eparine supersolfatate
ITPD940054A1 (it) *	1994-03-23	1995-09-23	Fidia Advanced Biopolymers Srl	Polisaccaridi solfatati
IT1306644B1 (it)	1999-04-08	2001-10-02	Fidia Advanced Biopolymers Srl	Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico.
CN103204950A (zh) *	2013-04-23	2013-07-17	李苹苹	一种贻贝蒸煮液中多糖类化合物的提纯方法
CN104497164A (zh) *	2015-01-26	2015-04-08	吉林大学	高压脉冲电场辅助酶解提取河蚌多糖工艺
GB2579600B (en)	2018-12-05	2023-07-05	Byotrol Plc	Anti-viral composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2832766A (en) *	1952-04-17	1958-04-29	Univ Ohio State Res Found	Sulfated aminopolysaccharides
GB740152A (en) *	1952-08-26	1955-11-09	Abbott Lab	Sulfate esters of partially degraded chitin and salts thereof

1978
- 1978-11-01 SE SE7811306A patent/SE7811306L/ not_active Application Discontinuation
1979
- 1979-10-17 EP EP79200596A patent/EP0011322B1/de not_active Expired
- 1979-10-17 DE DE7979200596T patent/DE2962725D1/de not_active Expired
- 1979-10-17 AT AT79200596T patent/ATE945T1/de not_active IP Right Cessation
- 1979-10-19 ZA ZA00795596A patent/ZA795596B/xx unknown
- 1979-10-22 PT PT70352A patent/PT70352A/pt unknown
- 1979-10-23 AU AU52045/79A patent/AU5204579A/en not_active Abandoned
- 1979-10-29 FI FI793375A patent/FI793375A7/fi not_active Application Discontinuation
- 1979-10-29 NO NO793474A patent/NO793474L/no unknown
- 1979-10-30 JP JP14037879A patent/JPS5564523A/ja active Pending
- 1979-10-31 NZ NZ191991A patent/NZ191991A/xx unknown
- 1979-10-31 DK DK459679A patent/DK459679A/da not_active Application Discontinuation
- 1979-11-01 ES ES485623A patent/ES485623A1/es not_active Expired

Also Published As

Publication number	Publication date
EP0011322B1 (de)	1982-05-05
PT70352A (en)	1979-11-01
FI793375A7 (fi)	1981-01-01
ATE945T1 (de)	1982-05-15
ES485623A1 (es)	1980-05-16
AU5204579A (en)	1980-05-08
DE2962725D1 (en)	1982-06-24
DK459679A (da)	1980-05-02
JPS5564523A (en)	1980-05-15
SE7811306L (sv)	1980-05-02
NZ191991A (en)	1982-05-25
ZA795596B (en)	1980-10-29
EP0011322A1 (de)	1980-05-28

Publication	Publication Date	Title
US4394373A (en)	1983-07-19	Method of achieving hemostasis
US4533549A (en)	1985-08-06	Antithrombotic agent
Banga	1953	Thermal contraction of collagen and its dissolution with elastase
US4500519A (en)	1985-02-19	Mucopolysaccharides having biological properties, preparation and method of use
US3766167A (en)	1973-10-16	Orally active anticoagulant
NO793474L (no)	1980-05-05	Antikoaguleringsmiddel og fremgangsmaate for fremstilling derav
Foster et al.	1955	The chemistry of heparin
US4804652A (en)	1989-02-14	Mucopolysaccharides having biological properties, preparation and application thereof as drugs
JPH04503950A (ja)	1992-07-16	平滑筋細胞増殖のインヒビターとしてのヘパリン断片
JPH051101A (ja)	1993-01-08	Ｎ，ｏ−硫酸化ヘパロザン、製法および医薬組成物
WO2017032276A1 (zh)	2017-03-02	一种牛肠粘膜依诺肝素钠及其制备方法与应用
US4870166A (en)	1989-09-26	Process for preparing high-purity dematan sulphate, and pharmaceutical compositions which contain it
JPH03243601A (ja)	1991-10-30	血液凝固の制御能をもつムコ多糖組成物およびその製造方法
JP2628507B2 (ja)	1997-07-09	Ｅｄｔａ不含のヘパリン、ヘパリン分画ならびに断片、それらの製造法及びそれらを含有する医薬品組成物
DK172798B1 (da)	1999-07-19	Fremgangsmåde til fremstilling af lavmolekylære hepariner ved depolymerisation af normal heparin
ITCO960031A1 (it)	1998-06-18	Fucani a basso peso molecolare aventi attivita' anticoagulante antitrombinica e antitrombotica
US5268366A (en)	1993-12-07	Polysaccharide composition or polysaccharide having heparinoid activity, process for producing the same, and anticoagulant containing the same as active ingredient
JPWO1999011671A1 (ja)	2002-08-13	真菌からの（１→３）−β−Ｄ−グルカンの調製法
JP2714718B2 (ja)	1998-02-16	新規硫酸化多糖及びその薬学的に許容される塩、その製造方法並びにそれを有効成分とする医薬
EP4360638A1 (de)	2024-05-01	Verwendung von sulfatgluco-galacto-oligosaccharid bei der herstellung eines antikoagulans und/oder eines antithrombotikums
CN109438589B (zh)	2021-04-23	一种具有缓和抗凝血作用的贝类肝素及其制备方法和应用
JPWO1990008784A1 (ja)	1991-01-10	新規硫酸化多糖及びその薬学的に許容される塩、その製造方法並びにそれを有効成分とする医薬
CN114316081B (zh)	2023-03-28	一种具有抑制SARS-CoV-2活性的长茎葡萄蕨藻硫酸化多糖及其制备方法和应用
DK175087B1 (da)	2004-05-24	Alkanoylestere af heparin, farmaceutisk præparat, der indeholder dem og anvendelse deraf
BR102024011053A2 (pt)	2025-12-16	Levana sulfatada de bacillus subtilis natto com capacidade antiviral, anticoagulante e antioxidante